This progressive lung disease transforms healthy tissue into stiff, scarred areas making breathing difficult. Learn the ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and tissues from patients with fatal IPF. The researchers discovered that disease ...

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) ...

GRI Bio is developing Natural Killer T cell modulators for treatment of inflammatory, fibrotic and autoimmune diseases. It reported the results from its continuing Phase 2a study demonstrating ...

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

The cells in human bodies are subject to both chemical and mechanical forces. But until recently, scientists have not ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

Gyre Therapeutics, Inc.’s GYRE share price has dipped by 14.60%, which has investors questioning if this is right time to buy ...

Pliant Therapeutics, Inc.’s PLRX share price has dipped by 10.89%, which has investors questioning if this is right time to ...

The Government's recently launched AI Action Plan, focusing on creating a National Data Library, marks a pivotal moment for ...